The association between radioresistance and tumour evolution

Impossible d'ajouter des articles

Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.

Veuillez réessayer plus tard

Échec de l’élimination de la liste d'envies.

Veuillez réessayer plus tard

Impossible de suivre le podcast

Impossible de ne plus suivre le podcast

The association between radioresistance and tumour evolution

Écouter gratuitement

Voir les détails

À propos de ce contenu audio

Is a tumour's ability to evolve and adapt over time linked to why it becomes resistant to radiotherapy? And if so, what can we do to overcome this radioresistance? In this episode, Dr Christopher Jones and Dr Ashley Nicholls from CRUK RadNet Cambridge at the University of Cambridge explore these questions. They explain why some tumours are resistant to radiation and why some patients are more resistant to treatment than others. They also offer insights into why recurrence happens and how to identify it early in order to treat it more effectively with new technologies. This includes designing new tools to make drug delivery more accurate and new genetic approaches to investigate specific ways to treat cancer in the context of radiation. Chris works predominantly in oesophageal cancer, while Ash studies lung cancer, but both strive to understand why relapse and radioresistance occur to then try to target these cancers with specific drugs or drug combinations to lessen toxicity and help personalise treatment.

Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !

Aucun commentaire pour le moment